OriV508, developed by Union Hospital and OriCell Therapeutics, targets relapsed/refractory hematological malignancies, specifically multiple myeloma and aggressive B-cell non-Hodgkin lymphoma. The market for CAR-T therapies is rapidly expanding, with significant competition from established players like Novartis and Gilead. Successful outcomes in this trial could position OriV508 as a viable treatment option, potentially capturing market share in a high-demand segment. The trial's single-arm design and focus on safety and preliminary efficacy will be critical for attracting investment and partnership opportunities, especially given the stringent eligibility criteria that may limit patient enrollment.